tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Indaptus Therapeutics Inc trading halted, volatility trading pause
PremiumThe FlyIndaptus Therapeutics Inc trading halted, volatility trading pause
2M ago
Indaptus Therapeutics Inc trading halted, news pending
Premium
The Fly
Indaptus Therapeutics Inc trading halted, news pending
2M ago
Indaptus Therapeutics Announces Reverse Stock Split
Premium
Company Announcements
Indaptus Therapeutics Announces Reverse Stock Split
2M ago
Indaptus Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany AnnouncementsIndaptus Therapeutics Approves Key Proposals at Annual Meeting
2M ago
Indaptus Therapeutics: Promising Clinical Developments and Strategic Advances Justify Buy Rating
Premium
Ratings
Indaptus Therapeutics: Promising Clinical Developments and Strategic Advances Justify Buy Rating
2M ago
Indaptus doses first patient in Phase 1b.2 study of Decoy20 withTislelizumab
Premium
The Fly
Indaptus doses first patient in Phase 1b.2 study of Decoy20 withTislelizumab
2M ago
Indaptus Therapeutics initiates Phase 1 study of Decoy20
PremiumThe FlyIndaptus Therapeutics initiates Phase 1 study of Decoy20
5M ago
Buy Recommendation for Indaptus Therapeutics: Promising Phase 1 Study and Financial Stability Boost Confidence
Premium
Ratings
Buy Recommendation for Indaptus Therapeutics: Promising Phase 1 Study and Financial Stability Boost Confidence
5M ago
Indaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last year
Premium
The Fly
Indaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last year
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100